The increased survival of the IL-13-PE treated mice helps to further validate the idea that targeted therapy against IL-13Rα2 expression could be employed as a clinical means of inhibiting HNSCC. The gene discussed is IL13RA2; the disease is head and neck squamous cell carcinoma.